Former Netflix VP Files Lawsuit Alleging Termination Over Medical Ketamine Treatment
Geordie Baillie, a former high-ranking Netflix executive, asserts the streaming giant fired him for treating clinical depression with prescribed ketamine. The legal filing highlights a clash between corporate policy and medically supervised mental health care.
Corporate Conflict Over Prescribed Mental Health Therapy
In a newly filed lawsuit, former Netflix executive Geordie Baillie claims his tenure at the company ended abruptly because he disclosed his participation in a medically supervised ketamine program. Baillie, who held a senior leadership role, asserts that the streaming service discriminated against him based on a health condition and the subsequent treatment path recommended by his physicians.
Timeline of the Dispute
The legal complaint outlines a series of events beginning in late 2022. Following the loss of his mother, Baillie sought professional help for clinical depression. He eventually enrolled in a ketamine therapy program at a specialized clinic in Santa Barbara. Key details from the filing include:
- Initial Secrecy: For several months, Baillie maintained his professional responsibilities while undergoing treatment privately.
- Disclosure: Baillie eventually informed his superiors about the treatment to ensure transparency regarding his medical needs.
- Termination: The plaintiff alleges that Netflix leadership reacted negatively to the disclosure, leading to his dismissal shortly thereafter.
Legal Bases for the Claim
The lawsuit focuses on allegations that Netflix violated labor laws regarding disability and medical leave. Baillie argues that ketamine therapy, while nontraditional in a corporate context, was an essential component of his recovery and should have been protected as a private medical matter. The complaint seeks damages for lost wages and emotional distress, challenging how modern corporations handle employees utilizing emerging psychiatric treatments.
Source: NDTV — World
